Cell fate in colon cancer stem cells: To GLI or not to GLI?

Mol Cell Oncol

Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.

Published: April 2018

Colon cancer is a heterogeneous tumor driven by subpopulations of cancer stem cells (CSCs). We recently used patient-derived organoids (PDOs) to demonstrate that CSC survival is regulated by autocrine non-canonical Hedgehog signaling, which acts as a positive regulator of Wnt signaling to block CSC differentiation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149873PMC
http://dx.doi.org/10.1080/23723556.2018.1445940DOI Listing

Publication Analysis

Top Keywords

colon cancer
8
cancer stem
8
stem cells
8
cell fate
4
fate colon
4
cells gli
4
gli gli?
4
gli? colon
4
cancer heterogeneous
4
heterogeneous tumor
4

Similar Publications

The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.

View Article and Find Full Text PDF

Isoflavones are currently being investigated by researchers in order to demonstrate their ability to prevent the proliferation of cancer cells. The current review aimed to demonstrate the potential of isoflavones to eliminate cancerous cells in the stomach, liver, lung, breast, and prostate, as their anticancer properties are due to the ability to block the signaling pathways of the extracellular signal-controlled kinase (MAPK/ERK) and proteasome (PI3K/AKT/mTOR). Isoflavones can inhibit the cell division of various cancer cells.

View Article and Find Full Text PDF

Highly efficient isolation and multistep analysis of tumor cells from whole blood.

Lab Chip

March 2025

Robert Bosch GmbH, Corporate Sector Research and Advance Engineering, Robert-Bosch-Campus 1, 71272 Renningen, Germany.

We present a microfluidic solution for improved tumor cell analysis based on selection-free isolation of nucleated cells from whole blood. It consists of a high-density silicon microcavity array combined with the novel fluidic strategy of microfluidic decanting. This enables multistep on-chip staining protocols comprising sample loading-blocking-extracellular staining-fixation-permeabilization and intracellular staining to quantify tumor cells.

View Article and Find Full Text PDF

Introduction: Colorectal cancer (CRC) is a type of cancer that develops due to abnormal cell growth in the colon and rectum. Existing conventional CRC treatment strategies have side effects. Hence, exploring new and advanced techniques for bacterial CRC therapy is crucial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!